• Home
  • E-submission
  • Sitemap
  • Contact us
  • Search
  • Advanced Search
Intest Res Search

CLOSE

‘Intestinal Research’ (Intest Res) is the joint official publication of the Asian Organization for Crohn's and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn's Foundation (India) (CCF, india).
The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance.As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines.

Review

May 31, 2022


Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies
Priscila A. Lima, Bárbara B. Berg, Marina Gomes Miranda e Castor
Intest Res. 2022;20(4):392-417.

The components of the endogenous cannabinoid system are widely expressed in the gastrointestinal tract contributing to local homeostasis. In general, cannabinoids exert inhibitory actions in the gastrointestinal tract, inducing anti-inflammatory,...

Review

December 2, 2021


Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intest Res. 2022;20(4):418-430.

Over the past decades, there has been a rapid increase in the incidence and prevalence of inflammatory bowel disease (IBD) in Asia. The natural history of IBD in Asian patients...

Statement

January 5, 2022


Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements
Yong Eun Park, Yoo Jin Lee, Ji Young Chang, et al.
Intest Res. 2022;20(4):431-444.

Many unexpected problems have resulted from the unprecedented coronavirus disease 2019 (COVID-19) pandemic. The optimal management of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic has also been...

Original Article

February 8, 2022


Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study
Anurag Mishra, Amarender Singh Puri, Sanjeev Sachdeva, et al.
Intest Res. 2022;20(4):445-451.

Background/Aims: Response to vaccine in patients with inflammatory bowel disease is lower than in the general population. We aimed to evaluate the efficacy of hepatitis B virus (HBV) vaccination in...

Original Article

March 11, 2022


Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, et al.
Intest Res. 2022;20(4):452-463.

Background/Aims: Epidemiological data on steroid use in South Korean patients with inflammatory bowel disease (IBD) are limited. We documented the steroid use patterns in these patients, and whether physician education...

Original Article

March 31, 2022


Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
Haruka Otake, Satohiro Matsumoto, Hirosato Mashima
Intest Res. 2022;20(4):464-474.

Background/Aims: Although anti-tumor necrosis factor (TNF)-α agents are important therapeutic drugs for Crohn’s disease (CD), data regarding their long-term sustained effects are limited. Herein, we evaluated the long-term loss of...

Original Article

June 13, 2022


Clinical features of very early-onset inflammatory bowel disease in Japan: a retrospective single-center study
Masaaki Usami, Ichiro Takeuchi, Reiko Kyodo, et al.
Intest Res. 2022;20(4):475-481.

Background/Aims: Very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed in patients younger than 6 years, is a challenge for pediatric gastroenterologists. Although there have been reports regarding VEO-IBD...

Original Article

April 15, 2022


Gastrointestinal bleeding risk of non-vitamin K antagonist oral anticoagulants versus warfarin in general and after polypectomy: a population-based study with propensity score matching analysis
Jong Yop Pae, Eun Soo Kim, Sung Kook Kim, et al.
Intest Res. 2022;20(4):482-494.

Background/Aims: Gastrointestinal bleeding (GIB) risk for non-vitamin K antagonist oral anticoagulants (NOACs) compared with warfarin is largely unknown. We aimed to determine the risk of overall and post-polypectomy GIB for...

Original Article

August 8, 2022


Abdominal aortic calcification in patients with inflammatory bowel disease: does anti-tumor necrosis factor α use protect from chronic inflammation-induced atherosclerosis?
Aikaterini Mantaka, Nikolaos Galanakis, Dimitrios Tsetis, et al.
Intest Res. 2022;20(4):495-505.

Background/Aims: Abdominal aortic calcium (AAC) deposition has been suggested as a marker of early atherosclerosis. There is no published data on the evaluation of AAC in inflammatory bowel disease (IBD). Methods:...
Current Issue
Volume 20(4); Oct 2022
Corticosteroid, a double-edged sword in inflammatory bowel disease management: possibility of reducing corticosteroid use through physician education
Seulji Kim, Seong-Joon Koh
Intest Res. 2022;20(4):389-391.

Editorial

Epub October 28, 2022
Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies
Priscila A. Lima, Bárbara B. Berg, Marina Gomes Miranda e Castor
Intest Res. 2022;20(4):392-417.

Review

Epub May 31, 2022
Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intest Res. 2022;20(4):418-430.

Review

Epub December 2, 2021
Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements
Yong Eun Park, Yoo Jin Lee, Ji Young Chang, et al.
Intest Res. 2022;20(4):431-444.

Statement

Epub January 5, 2022
Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study
Anurag Mishra, Amarender Singh Puri, Sanjeev Sachdeva, et al.
Intest Res. 2022;20(4):445-451.

Original Article

Epub February 8, 2022
Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, et al.
Intest Res. 2022;20(4):452-463.

Original Article

Epub March 11, 2022
Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
Haruka Otake, Satohiro Matsumoto, Hirosato Mashima
Intest Res. 2022;20(4):464-474.

Original Article

Epub March 31, 2022
Clinical features of very early-onset inflammatory bowel disease in Japan: a retrospective single-center study
Masaaki Usami, Ichiro Takeuchi, Reiko Kyodo, et al.
Intest Res. 2022;20(4):475-481.

Original Article

Epub June 13, 2022
Gastrointestinal bleeding risk of non-vitamin K antagonist oral anticoagulants versus warfarin in general and after polypectomy: a population-based study with propensity score matching analysis
Jong Yop Pae, Eun Soo Kim, Sung Kook Kim, et al.
Intest Res. 2022;20(4):482-494.

Original Article

Epub April 15, 2022
Abdominal aortic calcification in patients with inflammatory bowel disease: does anti-tumor necrosis factor α use protect from chronic inflammation-induced atherosclerosis?
Aikaterini Mantaka, Nikolaos Galanakis, Dimitrios Tsetis, et al.
Intest Res. 2022;20(4):495-505.

Original Article

Epub August 8, 2022
Novel inflammatory bowel disease (IBD) specific electronic medical record allows scalable auditing of IBD severity, therapy and complications to show the current unmet need in IBD care
Alex Barnes, David Carter, Patricia Kaazan, et al.
Intest Res. 2022;20(4):506-508.

Brief Communication

Epub April 26, 2022
Urinary chitinase 3-like 1 and intestinal fatty-acid binding proteins are not elevated in children with inflammatory bowel disease
Shaun Siong Chung Ho, Jacqueline Ilene Keenan, Andrew Stewart Day
Intest Res. 2022;20(4):509-513.

Letter to the Editor

Epub July 22, 2022
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD
ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 310, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2022 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next
Close layer
prev next